Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed

Executive Summary

Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.

You may also be interested in...



Accelerating Antibiotics: Kevin Outterson And Joe Larsen Explain CARB-X

Podcast with CARB-X Executive Director Kevin Outterson and BARDA Acting Deputy Director Joe Larsen describes the work of the accelerator, which just announced the first eleven projects in its portfolio.

CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands

The biotech startups that will be supported by a new transatlantic public-private partnership could end up with innovative products enticing enough to get some large biopharmaceutical firms back into the antibiotic game.

CMS Denial of Astellas’ Cresemba Add-On Payment Could Boost Legislative Solution

Bad news might be good news in the long term if Astellas’ woes highlight need for special antimicrobial reimbursement, which is one provision of the 21st Century Cures Act.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel